

Fall 2019 Review Cycle

Cancer Measure Evaluation Recusals

The [NQF CDP Conflict of Interest Policy](#) requires that Committee members identified as having a potential conflict of interest in relation to specific measures must recuse themselves from evaluation and voting on those measures when seated on the Committee.

In the review of disclosure of interests submitted by Committee members, NQF is requiring the following recusals be made during the measure evaluation period.

Measures Under Review (Fall 2019) and Committee Member Recusals

Measure Number	Measure Title	Measure Steward	Committee Member Recusals
0219	Radiation therapy is administered within 1 year (365 days) of diagnosis for women under age 70 receiving breast conserving surgery for breast cancer	American College of Surgeons, Commission on Cancer	<p>Matthew Facktor, MD, FACS Director, Department of Thoracic Surgery Geisinger Medical Center</p> <p>Robert Rosenberg, MD, FACP Radiologist Radiology Associates of Albuquerque</p>
0220	Adjuvant hormonal therapy is recommended or administered within 1 year (365 days) of diagnosis for women with AJCC T1cN0M0, or stage IB - III hormone receptor-positive breast cancer	American College of Surgeons, Commission on Cancer	<p>Matthew Facktor, MD, FACS Director, Department of Thoracic Surgery Geisinger Medical Center</p> <p>Robert Rosenberg, MD, FACP Radiologist Radiology Associates of Albuquerque</p>

Measure Number	Measure Title	Measure Steward	Committee Member Recusals
0223	Adjuvant chemotherapy is recommended or administered within 4 months (120 days) of diagnosis to patients under the age of 80 with AJCC III (lymph node positive) colon cancer	American College of Surgeons, Commission on Cancer	<p>Matthew Facktor, MD, FACS Director, Department of Thoracic Surgery Geisinger Medical Center</p> <p>Robert Rosenberg, MD, FACR Radiologist Radiology Associates of Albuquerque</p>